IRIS
DI RAIMONDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.745
EU - Europa 9.169
AS - Asia 4.586
AF - Africa 559
SA - Sud America 60
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 19
Totale 33.162
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.913
IE - Irlanda 2.709
UA - Ucraina 2.443
CN - Cina 2.323
IT - Italia 2.063
SG - Singapore 1.906
CA - Canada 824
RU - Federazione Russa 670
CI - Costa d'Avorio 405
SE - Svezia 284
DE - Germania 271
GB - Regno Unito 153
SN - Senegal 137
VN - Vietnam 112
FR - Francia 103
CH - Svizzera 88
IN - India 60
NL - Olanda 60
FI - Finlandia 55
BR - Brasile 48
UZ - Uzbekistan 48
AT - Austria 46
BE - Belgio 46
GR - Grecia 45
CZ - Repubblica Ceca 39
PL - Polonia 38
LB - Libano 32
JP - Giappone 23
ES - Italia 21
EU - Europa 19
AU - Australia 17
IR - Iran 17
HK - Hong Kong 16
NG - Nigeria 10
BG - Bulgaria 9
NO - Norvegia 8
KR - Corea 7
NZ - Nuova Zelanda 7
TR - Turchia 6
AR - Argentina 5
IL - Israele 5
MX - Messico 5
AZ - Azerbaigian 4
BD - Bangladesh 4
MA - Marocco 4
RS - Serbia 4
TH - Thailandia 4
LU - Lussemburgo 3
MY - Malesia 3
SI - Slovenia 3
AE - Emirati Arabi Uniti 2
CL - Cile 2
EG - Egitto 2
KW - Kuwait 2
KZ - Kazakistan 2
PH - Filippine 2
PT - Portogallo 2
RO - Romania 2
BH - Bahrain 1
BO - Bolivia 1
CO - Colombia 1
DK - Danimarca 1
EC - Ecuador 1
EE - Estonia 1
GL - Groenlandia 1
HR - Croazia 1
ID - Indonesia 1
IQ - Iraq 1
JM - Giamaica 1
JO - Giordania 1
LK - Sri Lanka 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
PY - Paraguay 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 33.162
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.920
Jacksonville 2.708
Dublin 2.692
Chandler 2.205
Singapore 1.351
Boardman 1.150
Chicago 942
Catania 807
Nanjing 769
Cambridge 740
Andover 735
Lawrence 734
Toronto 657
Houston 493
Ashburn 445
Des Moines 435
Abidjan 405
San Mateo 401
Nanchang 271
Wilmington 266
Civitanova Marche 232
Shenyang 187
Saint Petersburg 186
Hebei 181
Jiaxing 151
Ottawa 151
Changsha 137
Dakar 137
Tianjin 111
Grafing 99
Dong Ket 87
Los Angeles 65
Moscow 61
Beijing 57
Florence 57
Washington 54
Seattle 50
Munich 47
Rome 47
Brussels 45
Hangzhou 44
Milan 40
Den Haag 39
Norwalk 38
Helsinki 37
Kunming 37
Palermo 35
Bremen 32
Falls Church 32
Pune 31
Jinan 29
Hanoi 23
Brno 22
Liberty Lake 21
Ann Arbor 20
Guangzhou 19
Frankfurt Am Main 18
Redwood City 18
Hanover 17
Lappeenranta 17
Ningbo 17
Maracena 15
Taizhou 15
Zhengzhou 15
Ludwigshafen 14
Tokyo 14
Augusta 13
Bari 13
Hong Kong 13
Edinburgh 12
Messina 12
Turin 12
Ardabil 11
Lausanne 11
Misterbianco 11
Abuja 10
Bologna 10
Dearborn 10
Genoa 10
Mountain View 10
Redmond 10
Changchun 9
Portland 9
Lanzhou 8
Monmouth Junction 8
Oslo 8
Paris 8
Princeton 8
Amsterdam 7
Leawood 7
Mascalucia 7
Naples 7
Seoul 7
Tappahannock 7
Verona 7
Fukuoka 6
Fuzhou 6
Giardini-Naxos 6
Padova 6
San Giovanni la Punta 6
Totale 24.232
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 225
Childhood neurofibromatosis type 2 (NF2) and related disorders: From bench to bedside and biologically targeted therapies [Neurofibromatosi tipo 2 (NF2) e sindromi correlate in età infantile: dalla biologia molecolare alla pratica clinica e nuove terapie con farmaci biologici] 210
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 158
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload 154
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 137
Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. 124
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 119
Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib 104
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 103
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 102
Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification 100
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia 91
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM) 84
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells 84
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 83
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. 82
Terapia del mieloma multiplo 81
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 80
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen 79
Mesenchymal stem cells (MSC) promotes tumor microenvironment transformation driving Granulocyte-like Myeloid Derived Suppressor Cells (G-MDSC) activation in Smoldering and Multiple Myeloma patients 78
NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 77
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 76
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 76
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 76
Cementoplasty in the management of painful extraspinal bone metastases: our experience 75
A PHASE III STUDY OF ENOXAPARIN VERSUS ASPIRIN VERSUS LOW-DOSE WARFARIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED UP-FRONT WITH THALIDOMIDE BASED-REGIMENS 75
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 75
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 74
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 74
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 73
The Apoptotic Machinery As A Biological Complex System: Analysis of its Omics and Evolution, Identification of Candidate Genes for Fourteen Types of Cancer and Experimental Validation in CML and Neuroblastoma 73
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 73
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 73
A snapshot of asparaginase-induced liver insufficiency. 72
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 72
The Apoptotic Machinery As A Biological Complex System: Analysis Of Its Omics And Evolution, Identification Of Candidate Genes For Fourteen Major Types Of Cancer And Experimental Validation in CML And Neuroblastoma 72
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines 72
Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood 71
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 71
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 71
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 71
Vg9Vd2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells 70
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 70
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 70
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 70
Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML 69
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 69
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 69
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 69
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 68
Lymphoma of the cecum: a case report 68
Acute pre-hepatic portal thrombosis: diagnosis and therapy 68
Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes 68
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma 68
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 68
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 67
PREDICTORS FOR RESPONSE TO RUXOLITINIB IN REAL-LIFE: AN OBSERVATIONAL INDEPENDENT STUDY ON 266 PATIENTS WITH MYELOFIBROSIS 67
Uncommon long-term survival in a patient with chronic myeloid leukemia 67
Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile 67
Bone turnover markers in patients with type 1 Gaucher disease 67
Effects of imatinib mesylate in osteoblastogenesis 66
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 66
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 66
Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. 66
The Apoptotic Machinery As A Biological Complex System: Analysis of its Omics, Identification of Candidate Genes for Fourteen Major Types of Cancer and Experimental Validation in CML and Neuroblastoma 66
Rate of fungal infections in patients with acute myeloid leukemia during induction treatment performing two prophylactic strategies: preliminary results 66
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 66
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 66
Bortezomib for the treatment of previously untreated multiple myeloma. 65
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 65
Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia 65
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD 65
Il Rasario. Semeiotica medica 65
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 65
Angiogenesis in acute myeloid leukemia 64
The Apoptotic Machinery As A Biological Complex System: Analysis Of Its Omics And Evolution, Identification Of Candidate Genes For Fourteen Major Types Of Cancer And Experimental Validation in CML And Neuroblastoma 64
Clinical and Endoscopic Presentation of Primary Gastric Lymphoma: An Italian Multicenter Study 64
Hypoxia Induces Imatinib Resistance in CML Cell Lines 64
Detection of fungal dna in lysis-centrifugation blood culture for the prevision of response to antifungal in aml patients with persistent neutropenic fever: a pilot subset 64
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 64
Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report 64
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 64
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 63
In vitro sensitivity of B-CLL cells to Fludarabine and Interferons 63
ARGINASE 1 IS A MARKER OF MYELOID-MEDIATED IMMUNOSUPPRESSION WITH PROGNOSTIC MEANING IN CLASSIC HODGKIN'S LYMPHOMA 63
NEUTROPHIL TO LYMPHOCYTE RATIO IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 63
Lithium and acute myeloid leukemia. 63
Different in vitro alemtuzumab induced apoptosis on T and B lymphocytes of B-CLL patients 63
IMATINIB INCREASES CYTOTOXICITY OF MELPHALAN AND DECREASES PROLONGATION OF G2-M PHASE IN HUMAN K562 CELLS 63
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 63
Antitumor Activity of Bortezomib Alone and in Combination with TRAIL in Human Acute Myeloid Leukemia 63
Eventi avversi e trigger C12: Stroke in ospedale 63
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 63
SMOLDERING MYELOMA: WALKING THROUGH RISK FACTORS AND TENTATIVE CLASSIFICATION SYSTEMS 62
HIGH-RESOLUTION SNP ARRAYS AS AN ADDITIONAL TOOL TO SEARCH FOR GENETIC DEFECTS INVOLVED IN PROGRESSION FROM MYELODYSPLASTIC SINDROME TO ACUTE LEUKEMIA 62
Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients 62
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells 62
Multidrug resistance mechanisms in chronic lymphocytic leukaemia 62
A PHASE 3, RANDOMIZED CLINICAL STUDY OF AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE AT DIAGNOSIS 62
CD200 EXPRESSION ON MYELOMA CELLS AND ANTITUMOR IMMUNITY 62
Totale 7.676
Salva come PNG Salva come JPEG
Categoria #
all - tutte 127.172
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 127.172
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.522 0 0 0 0 0 58 326 21 439 34 453 191
2020/20214.051 39 397 581 81 1.210 68 551 13 487 8 436 180
2021/20225.309 657 783 22 44 893 42 782 180 541 28 123 1.214
2022/20237.660 767 284 104 520 733 1.424 24 1.313 2.038 63 279 111
2023/20243.223 215 439 135 261 142 523 68 212 18 86 690 434
2024/20257.383 104 2.142 856 452 2.867 962 0 0 0 0 0 0
Totale 34.218